Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up

James M. Roberts, Tekoa L. King, John R. Barton, Stacy Beck, Ira M. Bernstein, Tiffani E. Buck, Michele A. Forgues-Lackie, Francesca L. Facco, Alison D. Gernand, Cornelia R. Graves, Arundhati Jeyabalan, Alisse Hauspurg, Tracy A. Manuck, Jenny E. Myers, Trashaun M. Powell, Elizabeth F. Sutton, Elizabeth Tinker, Eleni Tsigas, Leslie Myatt

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Preeclampsia is a multisystemic disorder of pregnancy that affects 250,000 pregnant individuals in the United States and approximately 10 million worldwide per annum. Preeclampsia is associated with substantial immediate morbidity and mortality but also long-term morbidity for both mother and offspring. It is now clearly established that a low dose of aspirin given daily, beginning early in pregnancy modestly reduces the occurrence of preeclampsia. Low-dose aspirin seems safe, but because there is a paucity of information about long-term effects on the infant, it is not recommended for all pregnant individuals. Thus, several expert groups have identified clinical factors that indicate sufficient risk to recommend low-dose aspirin preventive therapy. These risk factors may be complemented by biochemical and/or biophysical tests that either indicate increased probability of preeclampsia in individuals with clinical risk factors, or more importantly, identify increased likelihood in those without other evident risk. In addition, the opportunity exists to provide this population with additional care that may prevent or mitigate the short- and long-term effects of preeclampsia. Patient and provider education, increased surveillance, behavioral modification, and other approaches to improve outcomes in these individuals can improve the chance of a healthy outcome. We assembled a group with diverse, relevant expertise (clinicians, investigators, advocates, and public and private stakeholders) to develop a care plan in which providers and pregnant individuals at risk can work together to reduce the risk of preeclampsia and associated morbidities. The plan is for care of individuals at moderate to high risk for developing preeclampsia, sufficient to receive low-dose aspirin therapy, as identified by clinical and/or laboratory findings. The recommendations are presented using the GRADE methodology with the quality of evidence upon which each is based. In addition, printable appendices with concise summaries of the care plan's recommendations for patients and healthcare providers are provided. We believe that this shared approach to care will facilitate prevention of preeclampsia and its attendant short- and long-term morbidity in patients identified as at risk for development of this disorder.

Original languageEnglish (US)
Pages (from-to)193-213
Number of pages21
JournalAmerican journal of obstetrics and gynecology
Volume229
Issue number3
DOIs
StatePublished - Sep 2023

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this